No Trump Cards for This Risk
This Insight is an update from Generic Drug Antitrust Inquiry: A Primer. Several generic drug companies caught up in government investigations into...
353 Views
Generic Drug Antitrust Inquiry: A Primer
Recent news stories reporting looming criminal antitrust charges against certain generic drug companies (and possibly executives) are wighing on...
396 Views
Mylan N.V. (MYL US): Another Contrarian Pharmaceutical Investment
Mylan Nv (MYL US) stock has seen some downward pressure since 2015 after the increased capital expenditure and debt load for acquisitions...
624 Views
Neurocrine Biosciences: An Attractive Takeover Candidate with Potential >50% Upside.
FDA has accepted the New Drug Application (NDA) for Neurocrine Biosciences Inc (NBIX US) Valbenazine for the treatment of Tardive Dyskinesia (with...
576 Views
The Chickens Are Ready to Roost
Several recent developments confirm our thesis that Inflectra's US sales in 2017 will fall far short of management's 2017 forecast. First, Pfizer's...
337 Views